Cannabidiol

• Published in: Clinical journal of oncology nursing Vol. 25; no. 4; pp. 405 - 412
• Main Authors: Butler, Taylor W, Hande, Karen, Ryan, Michelle, Raman, Rameela, McDowell, Rachel, Cones, Bethany, Jackson PhD APRN FNP-BC NEA-BC, Heather Jane, Cortez, Manuel, Murphy, Barbara A
• Format: Journal Article
• Language: English
• Published: Pittsburgh Oncology Nursing Society 01.08.2021
• Subjects: Anxiety; Back pain; Cancer therapies; Cannabidiol; Case reports; Chemotherapy; Clinical trials; Drug use; Fatigue; FDA approval; Marijuana; Medical diagnosis; Multiple myeloma; Narcotics; Nausea; Oncology; Pain; Pain management; Patients; Peripheral neuropathy; Quality of life; Side effects; United States > US
• DOI: 10.1188/21.CJON.405-412
• ISSN: 1092-1095

Patients for whom conventional treatments provide insufficient results may seek alternative treatments, such as cannabidiol (CBD), to mitigate symptoms, enhance quality of life and well-being, boost the immune system, or treat a disease (Richardson et al., 2000; Sparber et al., 2000). CASE STUDY A 62-year-old man with a history of multiple myeloma presents with fatigue, chemotherapy-induced peripheral neuropathy, and back pain. According to the National Cancer Institute (2018), the only documented benefits of CBD include anxiolytic, antiemetic, and anti-inflammatory effects. Two additional studies examined participants' pain relief during kidney transplantation and acute graft-versus-host disease after a bone marrow transplantation; again, the results were inconclusive because of sample size (Cuñetti et al., 2018; Yeshurun et al., 2015).